Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757415 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL31631383 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL31624478 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL23014555 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL30616161 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL23014554 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL30951506 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL22289774 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL22289775 | 1.00 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A | |
| SCHEMBL16539057 | 0.99 | TLR2 (0.50) | TLR2GLP1RMDM2TLR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250188019-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | ELI LILLY AND COMPANY | 2025-06-12 | — | — | US | disclosed |
| EP-4392404-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | Eli Lilly and Company (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028466-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | ELI LILLY AND COMPANY (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188019-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | AQP1, CCNB1, CDK2 | TLR2 4588/4885GLP1R 3553/4885MDM2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.